FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
What happened
FDA inspected the Canton, Massachusetts site from October 9 to November 5, 2025; the site is registered as an outsourcing facility, a compounder that makes sterile drugs in advance rather than for one named patient. Investigators saw operators' arms blocking sterile first air to vancomycin vials, vials shaken hard enough to disrupt unidirectional airflow, smoke studies that did not reflect real production conditions, and gaps in cleaning, environmental monitoring and investigation of leaking IV bags. The firm recalled various lots of drugs made with certain IV bags on February 5, 2026 because sterility could not be assured.
What FDA found
Sterile drugs were handled in conditions that could contaminate them: operators' arms blocked the first air reaching sterile vials, vials were shaken vigorously, and smoke studies did not show airflow under real production conditions.
FDCA section 501(a)(2)(A)The quality unit did not make sure drug products met their established specifications for identity, strength, quality and purity.
21 CFR 211.22The firm did not thoroughly investigate unexplained discrepancies or batch failures, and kept using IV bags with a known port-defect trend without a root cause or a pause in production.
21 CFR 211.192The firm lacked adequate written procedures, including validation, to prevent microbiological contamination of products meant to be sterile.
21 CFR 211.113(b)Air monitoring in the aseptic areas was inadequate, and the written procedure for placing settle plates did not cover the ISO 5 work area.
21 CFR 211.42(c)(10)(iv)Cleaning and disinfection of aseptic rooms was inadequate (rust-like residue on hood wheelbases) and the buildings were not kept in good repair (chipped paint, a divot in the floor).
21 CFR 211.42(c)(10)(v); 21 CFR 211.58
What FDA wants
FDA asks the company to write back within 15 working days with the specific steps taken to fix each violation, how recurrence will be prevented, and supporting documentation, or an explanation of why more time is needed. FDA also strongly recommends a full assessment of the aseptic operations with help from a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- hospitals, clinics and pharmacies that buy compounded sterile drugs from outsourcing facilities
- companies buying or distributing IV fluid bags and sterile compounds made at this site
- other 503B outsourcing facilities with similar aseptic filling and airflow controls
This is a summary. Read the original letter on fda.gov.